Slideseton: ThatcherN,HirschFR,LuftAV, first-herapyinpatientswithstageIVsquamousnon-small-celllungcancer(SQUIRE):anopen-label,randomized,;16:763-:ImprovedSurvivalWithNecitumumab+Gemcitabine/CisplatinvsGemcitabine/CisplatinasFirst-reatmentinPatientsWithSquamousNSCLCThisactivityissupportedbyeducationalgrantsfromGenentech,Lilly,,butweaskthatcontent withoutpermissionfromClinicalCareOptions (emailpermissions@)Disclaimer Omaterial,notthoseofClinicalCareOptions,LLC,theCMEproviders,:NecitumumabinAdvancedSquamousNSCLCPlatinum-baseddoubletchemotherapylongtimestandardfirst-reatmentoptionforthe~30%ofptswithsquamousNSCLC[1]Necitumumab:fullyhumanIgG1anti–EGFRmAbAdditiontogemcitabine/cisplatinincreasedantitumoractivityinmousexenograftmodelsofNSCLC[2]FailedtoimproveOSwhenaddedtopemetrexed/cisplatininptswithadvancednonsquamousNSCLCinphaseIIIINSPIREtrial[3]PhaseIIISQUIREtrialevaluatedsafety,efficacyofnecitumumab+gemcitabine/cisplatinvsgemcitabine/cisplatininchemotherapy-naiveptswithstageIVsquamousNSCLC[1],;16:763-,;9:77--AresL,;16:328-:SQUIRE:PhaseIIIStudySchemaPrimaryendpoint:OS(ITT)Secondaryendpoints:PFS,ORR,TTF,safetyThatcherN,;16:763-(0-1vs2) andgeographicregion (NorthAmerica/E
cco-lung-fellows-thatcher-lo-鳞癌 来自淘豆网m.daumloan.com转载请标明出处.
